Cyclopamine

製品コードS1146 別名:11-deoxojervine

Cyclopamine化学構造

分子量(MW):411.62

Cyclopamineは一種の特異性的なHedgehog信号経路拮抗剤で、TM3Hh12細胞にSmoothened (Smo)に作用する時のIC50値が46nMです。

サイズ 価格(税別)  
JPY 24402.00
JPY 44820.00
JPY 61420.00
JPY 78020.00

カスタマーフィードバック(4)

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

製品安全説明書

Hedgehog/Smoothened阻害剤の選択性比較

生物活性

製品説明 Cyclopamineは一種の特異性的なHedgehog信号経路拮抗剤で、TM3Hh12細胞にSmoothened (Smo)に作用する時のIC50値が46nMです。
ターゲット
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外試験

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq5VmljUUN3ME21Mlg3PjZizszN MoTpV2FPT0WU
DOHH-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTlwM{W2PFkh|ryP NX\uVol5W0GQR1XS
no-10 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4iyUGlEPTB;OT65NFM6KM7:TR?= MmfIV2FPT0WU
LS-513 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvyTWM2OD1zMT6zOVQ4KM7:TR?= MWLTRW5ITVJ?
ALL-PO NX7Wb4VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH36U4JKSzVyPUGxMlc4OzRizszN NVLIeWlwW0GQR1XS
8-MG-BA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXBUI5KSzVyPUGzMlEyOjNizszN M3rINHNCVkeHUh?=
RPMI-8402 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF3Lki1N|ch|ryP MnznV2FPT0WU
EoL-1-cell MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO5TWM2OD1zOD61PVQ5KM7:TR?= M4HwUHNCVkeHUh?=
NALM-6 M2K0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInKZ3pKSzVyPUG5MlAyPjdizszN NGTTUlNUSU6JRWK=
DEL MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:zc4ljUUN3ME2yNE4yPDdzIN88US=> NWHzOogzW0GQR1XS
SR MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTtO5hCUUN3ME2yN{43PzF3IN88US=> MkHvV2FPT0WU
697 NU\JNYNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJ4Lk[xOVUh|ryP MoSxV2FPT0WU
COLO-829 NXruRnNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nKdmlEPTB;Mk[uPFQ5OyEQvF2= M1fKZ3NCVkeHUh?=
EVSA-T NYT2N|FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWzdGdKSzVyPUK3MlU2PjFizszN NHvGR4lUSU6JRWK=
ATN-1 M3q3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDXTWM2OD1|MT6yN|I6KM7:TR?= NILnfFlUSU6JRWK=
L-363 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLMTJRDUUN3ME2zNU44PDZzIN88US=> NICycYdUSU6JRWK=
LAMA-84 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PJd2lEPTB;M{KuOVIyOSEQvF2= NHPvd3lUSU6JRWK=
NOS-1 MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n4emlEPTB;M{SuNlk2PiEQvF2= NX7HdJhVW0GQR1XS
BB30-HNC NF\4SYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPNXHJKSzVyPUO0MlM{ODZizszN M{jvT3NCVkeHUh?=
BC-1 NVTVbnJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7LdGFKSzVyPUO3Mlk4PDZizszN MX7TRW5ITVJ?
IST-SL2 M2r1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH6yVZlKSzVyPUO4MlIzPCEQvF2= NYjwR3BnW0GQR1XS
D-392MG M1i3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTRyLkKyNVUh|ryP MYPTRW5ITVJ?
no-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n5UmlEPTB;NECuOVUzOSEQvF2= MmK4V2FPT0WU
LC4-1 NInq[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXDTWM2OD12MD64O|E3KM7:TR?= M3H1VHNCVkeHUh?=
A388 M1nLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy4cldKSzVyPUSyMlU5PDhizszN M2nHSnNCVkeHUh?=
NTERA-S-cl-D1 NIPzcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLFTWM2OD12Mj63NFc1KM7:TR?= M1\6[XNCVkeHUh?=
CESS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPnTWM2OD12ND6yNlMzKM7:TR?= MYHTRW5ITVJ?
RS4-11 M17rcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUftO3dLUUN3ME20PU4xQTN6IN88US=> NFvnd4tUSU6JRWK=
MS-1 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;QOmZRUUN3ME21NE46OzVzIN88US=> MVPTRW5ITVJ?
CTV-1 MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTVzLkC3OEDPxE1? MonVV2FPT0WU
D-502MG M2njPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO1OXNKSzVyPUWxMlYzPzFizszN NFn6NXJUSU6JRWK=
ML-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLlTWM2OD13Mj65NVk2KM7:TR?= MVzTRW5ITVJ?
SK-NEP-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLOTWM2OD13Mz6zPVI{KM7:TR?= NGnESZJUSU6JRWK=
LOXIMVI M4DVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7IS3FKSzVyPUWzMlU5QDRizszN MYnTRW5ITVJ?
DJM-1 NXro[WZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjZTWM2OD13Nj6zN|kyKM7:TR?= M1fTXXNCVkeHUh?=
GI-1 NF\RO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1y2RWlEPTB;NU[uOlE1QSEQvF2= MUfTRW5ITVJ?
IST-MES1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHpTWM2OD14MD61OFk{KM7:TR?= M{jvNnNCVkeHUh?=
MV-4-11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTZyLk[1N|gh|ryP NGrGSmFUSU6JRWK=
OVCAR-4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTZ|LkW2OVch|ryP NXPHdHF2W0GQR1XS
KE-37 Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLocJE6UUN3ME22Ok4zPjZ6IN88US=> NHfQRo5USU6JRWK=
D-542MG NIfpVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTZ6LkSxN|Uh|ryP NUPJeZRuW0GQR1XS
MHH-PREB-1 M4\q[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTw[YtKSzVyPUeyMlg1PDFizszN MV\TRW5ITVJ?
MRK-nu-1 NFr2ZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD6Z5R6UUN3ME23N{41PzB3IN88US=> MV7TRW5ITVJ?
D-247MG M{TUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTPV2ZKSzVyPUezMlU1PDJizszN M1\xPHNCVkeHUh?=
OCI-AML2 NX\vN2pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTuTWM2OD15Nj65N|Y6KM7:TR?= M1P1TXNCVkeHUh?=
LP-1 NIjPUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq3XGRKSzVyPUiyMlg4OzFizszN M1XqOnNCVkeHUh?=
HCC1599 NU[3V41MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XvNWlEPTB;OESuNlg{PyEQvF2= M3KwSHNCVkeHUh?=
KARPAS-45 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW2W|VnUUN3ME24OE43QTl{IN88US=> M1;DV3NCVkeHUh?=
BE-13 MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnhTWM2OD17OT6wOFc4KM7:TR?= NW\YO4JwW0GQR1XS
GCIY MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X1SmlEPTB;OUmuNFk2PCEQvF2= MVHTRW5ITVJ?
BV-173 MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7GXYVUUUN3ME2xNFAvOzJ3IN88US=> NIHwUGhUSU6JRWK=
LB2518-MEL M4PnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\NTWM2OD1zMECuO|g6KM7:TR?= MWrTRW5ITVJ?
KS-1 MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\jW2lEPTB;MUCxMlY{QSEQvF2= NHLPNIZUSU6JRWK=
MOLT-16 Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DpU2lEPTB;MUC0Mlk5PiEQvF2= NWjNOmozW0GQR1XS
NCI-H1770 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rSfWlEPTB;MUC4Mlc5PCEQvF2= M123TnNCVkeHUh?=
NCI-H82 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfqU2F4UUN3ME2xNVAvQTd4IN88US=> MlrpV2FPT0WU
NCCIT M4Llbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HrUWlEPTB;MUGyMlUzQSEQvF2= NUXSUZdYW0GQR1XS
KALS-1 M1eyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTFzNT65OFEh|ryP NYPvW|gxW0GQR1XS
LB2241-RCC NIezcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPITWM2OD1zMU[uOlc6KM7:TR?= MUjTRW5ITVJ?
HH NHLMd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFzNz6zPVUh|ryP MVTTRW5ITVJ?
HD-MY-Z M4qwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\4RphiUUN3ME2xNVgvPDh6IN88US=> M3zTe3NCVkeHUh?=
EB-3 NXrCPVNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF{Mz6wPVQh|ryP NYLiUXRLW0GQR1XS
BL-70 NVnhe3ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXSzOWNqUUN3ME2xNlMvOTJ5IN88US=> M3LEcHNCVkeHUh?=
K-562 M2THT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m1UWlEPTB;MUK2MlI1PSEQvF2= NV[2[5ptW0GQR1XS
HT-144 NFzSfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF|Mz6xOlQh|ryP Mnr5V2FPT0WU
PF-382 NYGw[ZpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L2VmlEPTB;MUO0MlM3OSEQvF2= M4LBd3NCVkeHUh?=
RPMI-8226 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\MZoNrUUN3ME2xN|UvODR3IN88US=> MUDTRW5ITVJ?
NCI-H1355 NVj6S2ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\NTWM2OD1zM{WuOVg4KM7:TR?= MkSxV2FPT0WU
LXF-289 MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF|OT63PFEh|ryP MYHTRW5ITVJ?
NCI-H69 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XCVWlEPTB;MUSyMlk{OiEQvF2= NXG0V3N{W0GQR1XS
SK-MEL-1 MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPrRYpKSzVyPUG0O{4yOyEQvF2= MlvKV2FPT0WU
KARPAS-299 NGfh[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF2OT6xNkDPxE1? NWnjS4I3W0GQR1XS
GB-1 NIDVfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG0TWM2OD1zNEmuN|IzKM7:TR?= M{\CTnNCVkeHUh?=
CMK MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LDSmlEPTB;MUS5MlUyPSEQvF2= NW\MOWI{W0GQR1XS
MPP-89 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF3Nj6wN|Uh|ryP MWrTRW5ITVJ?
KU812 NHjFVoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfJR5ZKSzVyPUG2NU46ODJizszN M3TEXnNCVkeHUh?=
REH NV3zPIZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvPRnFKSzVyPUG2Nk4yOjVizszN M4j0cXNCVkeHUh?=
NEC8 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW1b4k5UUN3ME2xOlUvODJ4IN88US=> NVOxUVlnW0GQR1XS
KP-N-YS NYD5OG17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzqdIZKSzVyPUG2PE4{QTVizszN MnPlV2FPT0WU
Ramos-2G6-4C10 M{XTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF4OT65NVUh|ryP NEfmXXdUSU6JRWK=
Becker MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH5SGZKSzVyPUG3OE4yQCEQvF2= MoDaV2FPT0WU
LB647-SCLC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnVcXdYUUN3ME2xO|UvQDR3IN88US=> MU\TRW5ITVJ?
LU-139 NH;RSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF5OD6wNVkh|ryP MV;TRW5ITVJ?
QIMR-WIL NYWwNWg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF5OT62OFYh|ryP MYLTRW5ITVJ?
NCI-H1395 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r0PGlEPTB;MUe5Mlk6PiEQvF2= NGntN4NUSU6JRWK=
NOMO-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPTTWM2OD1zOEKuPFUh|ryP MkDoV2FPT0WU
GI-ME-N MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7VTWM2OD1zOEeuPVY6KM7:TR?= MlHSV2FPT0WU
KMS-12-PE M1HVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LxUWlEPTB;MUi5MlI4OyEQvF2= MlS4V2FPT0WU
Daudi M{Dn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPUTWM2OD1zOUGuNVI5KM7:TR?= MV\TRW5ITVJ?
LB996-RCC M4Twbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLyTWM2OD1zOUGuOlk6KM7:TR?= M3q2RXNCVkeHUh?=
NCI-H2107 NXLodGtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLu[plKSzVyPUG5N{44OzlizszN NHPxTXRUSU6JRWK=
SK-PN-DW NY\zdYpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjPTWM2OD1zOUSuO|E6KM7:TR?= NWjFbZFjW0GQR1XS
MC-CAR M37ZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXaV4dKSzVyPUKwNk4zPTNizszN NIPZTWtUSU6JRWK=
SNB75 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P0bGlEPTB;MkKxMlk1KM7:TR?= Mn7uV2FPT0WU
ES4 NYPQdGZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n0dWlEPTB;MkKzMlc5OyEQvF2= MUDTRW5ITVJ?
KARPAS-422 M4Ltfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXhTWM2OD1{MkiuN|UzKM7:TR?= Mn7qV2FPT0WU
NCI-H1648 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK3UIp[UUN3ME2yNlkvPDh7IN88US=> Ml;ZV2FPT0WU
ES6 MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ|OT60N{DPxE1? MlXCV2FPT0WU
KNS-81-FD MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPnfodOUUN3ME2yOFEvOTl5IN88US=> MnLXV2FPT0WU
JAR MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm1XW9qUUN3ME2yOVYvOjJ3IN88US=> MXTTRW5ITVJ?
NB1 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ4MD61NVYh|ryP NHThUYlUSU6JRWK=
D-336MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPMTWM2OD1{NkCuOlk5KM7:TR?= MVzTRW5ITVJ?
BC-3 NELhO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrlRVl[UUN3ME2yOlUvOTd6IN88US=> NIr4fWtUSU6JRWK=
HCC2218 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7QTWM2OD1{Nk[uOFE2KM7:TR?= MmrDV2FPT0WU
TE-9 NUTONmIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJ4Nj62Nlch|ryP M3v6S3NCVkeHUh?=
LB1047-RCC NILs[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ4Nj63OVMh|ryP NYHrd|R5W0GQR1XS
CTB-1 NXfBPYFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\WUGlEPTB;Mk[5Mlk4OyEQvF2= MVzTRW5ITVJ?
NB7 NYHhSY5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TzdWlEPTB;MkexJO69VQ>? MnTOV2FPT0WU
ST486 MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH2b2ZUUUN3ME2yO|cvPDF{IN88US=> NW\PXGV3W0GQR1XS
HCC1187 NFrjN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJ6Mj64NVEh|ryP NGf1WIpUSU6JRWK=
NCI-SNU-16 M3HQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlexTWM2OD1{OESuNlQ5KM7:TR?= NXzEOlJWW0GQR1XS
COR-L279 M13xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ7MT61PFQh|ryP MWnTRW5ITVJ?
ES8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzhN4hKSzVyPUK5OE4yQDJizszN NVrvXpNrW0GQR1XS
U-698-M NV\tVpA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ7OD6yOFMh|ryP MVTTRW5ITVJ?
HEL NV\6eYlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rNWWlEPTB;M{C5MlE1QSEQvF2= NH;oVYRUSU6JRWK=
KINGS-1 MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH5TWM2OD1|MUCuOlc1KM7:TR?= Mk\qV2FPT0WU
KY821 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zi[GlEPTB;M{O2MlU6PSEQvF2= M17ScHNCVkeHUh?=
MZ1-PC NXzqN5lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\VTWM2OD1|NEWuOlE5KM7:TR?= NVjRTI81W0GQR1XS
LS-411N NH7heZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTN3ND62OkDPxE1? MVjTRW5ITVJ?
SIG-M5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XuWWlEPTB;M{W5Mlc5OiEQvF2= MX7TRW5ITVJ?
HT MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXjTWM2OD1|NkeuO|EyKM7:TR?= MWrTRW5ITVJ?
HC-1 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf0Sm5KSzVyPUO2O{44QDdizszN MWjTRW5ITVJ?
NCI-H1694 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDPTWM2OD1|N{KuPVM1KM7:TR?= MnjMV2FPT0WU
BB65-RCC NIS2TYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTN5Nj6yOFUh|ryP NVzpNolGW0GQR1XS
HAL-01 NXXENZNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX5fJl5UUN3ME2zO|kvQDN6IN88US=> NGGxTmhUSU6JRWK=
ARH-77 NVrhUXFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jj[GlEPTB;M{m0MlAxQCEQvF2= NWrjVXFnW0GQR1XS
MZ7-mel NYSwZYVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\zT|NKSzVyPUO5O{4zOzNizszN M3LiOXNCVkeHUh?=
SIMA M33ZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH6PIlyUUN3ME20NFMvQTN|IN88US=> MmnaV2FPT0WU
DG-75 NV;jZpk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPaTWM2OD12MUWuOlk5KM7:TR?= M{XPUnNCVkeHUh?=
HUTU-80 NXjRfHZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j5NmlEPTB;NEG5MlE5PSEQvF2= MWDTRW5ITVJ?
KNS-42 NF3zSYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\kTWM2OD12MkWuPFE2KM7:TR?= NF\1eFNUSU6JRWK=
SH-4 NHLtVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR{Nz61OlUh|ryP Mmr3V2FPT0WU
L-540 NX62XGdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFqxO|RKSzVyPUSzNU4xOzFizszN MWjTRW5ITVJ?
NB10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTR2MT6yN|Qh|ryP NUfBbpo5W0GQR1XS
ES1 NYPIO4djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzvXVZ{UUN3ME20OVIvPzV|IN88US=> MnjZV2FPT0WU
KMOE-2 NE\ZOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTR3Nj63NVEh|ryP MX\TRW5ITVJ?
MC116 NH7ZPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC1TWM2OD12NUiuNVE3KM7:TR?= MXnTRW5ITVJ?
RCC10RGB M2fzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHUTWM2OD12NkCuNFA2KM7:TR?= NILr[lNUSU6JRWK=
RL95-2 M1q5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTR4MD6yN|ch|ryP MUPTRW5ITVJ?
Raji MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;YT2lEPTB;NE[4MlE1OyEQvF2= NYK1NlNuW0GQR1XS
CAS-1 Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[5TWM2OD12N{KuNFc{KM7:TR?= NF\ad5NUSU6JRWK=
Calu-6 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fBZmlEPTB;NEe1MlI3PSEQvF2= NHmxUYpUSU6JRWK=
KG-1 NUnHeYpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz0TWM2OD12N{iuOFQh|ryP M1vBZXNCVkeHUh?=
LB771-HNC MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nEdmlEPTB;NEiyMlI{OiEQvF2= NX2wN3FzW0GQR1XS
ACN MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmKyTWM2OD12OUOuOVk6KM7:TR?= M{eybXNCVkeHUh?=
KM12 M{Difmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKxdIJKSzVyPUS5Ok42QDlizszN Ml[xV2FPT0WU

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
細胞試験: [2]
+ 展開
  • 細胞株: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • 濃度: Dissolved in DMSO, final concentration 3 μM
  • 反応時間: 4 days
  • 実験の流れ: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: 50 mg/kg/day
  • 投与方法: Subcutaneous injection
    (参考用のみ)

溶解度 (25°C)

体外 DMF 10 mg/mL (24.29 mM) warming
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble
体内 順序で溶剤を入れること:
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
1mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 411.62
化学式

C27H41NO2

CAS No. 4449-51-8
保管
別名 11-deoxojervine

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened信号経路図

Hedgehog/Smoothened Inhibitors with Unique Features

相関Hedgehog/Smoothened製品

Tags: Cyclopamineを買う | Cyclopamine ic50 | Cyclopamine供給者 | Cyclopamineを購入する | Cyclopamine費用 | Cyclopamine生産者 | オーダーCyclopamine | Cyclopamine化学構造 | Cyclopamine分子量 | Cyclopamine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID